LP220265-5
Sofosbuvir
Active
Description
Sofosbuvir (Sovaldi) is a nucleotide analogue NS5B polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection as a component of a combination antiviral treatment regimen. The replication of HCV requires NS5B, an RNA-dependent RNA polymerase, responsible for the synthesis of both positive-strand genomic RNA and negative-strand RNA. Sofosbuvir mimics the natural substrate of NS5B polymerase and becomes incorporated into the growing RNA, inducing a chain termination event. Sofosbuvir, as one of the nucleos(t)ide analog inhibitors, has a distinct resistance profile that does not overlap with the non-nucleoside NS5B protease inhibitors. Resistance to sofosbuvir is uncommon. The S282T mutation has been identified as the common variant to pose resistance to sofosbuvir, however, this variant is not generally found in untreated patients with HCV. PMID: 24883006 Source: Regenstrief LOINC
Basic Part Properties
- Part Display Name
- Sofosbuvir
- Part Type
- Component (Describes the core component or analyte measured)
- Created On
- 2016-06-24
- Construct for LOINC Short Name
- Sofosbuvir
LOINC Terminology Service (API) using HL7® FHIR® Get Info
Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.
- CodeSystem lookup
- https:
//fhir.loinc.org/CodeSystem/$lookup?system=http: //loinc.org&code=LP220265-5
Language Variants Get Info
| Tag | Language | Translation |
|---|---|---|
| zh-CN | Chinese (China) | 索非布韦 Synonyms: 索氟布韦; |
| es-ES | Spanish (Spain) | Sofosbuvir |
| it-IT | Italian (Italy) | Sofosbuvir |
| nl-NL | Dutch (Netherlands) | sofosbuvir |
LOINC Copyright
Copyright © 2024 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright